A @-week , dose-ranging , randomized , double-blind , placebo-controlled proof-of-concept study randomly assigned @ adults with type @ diabetes ( HbA@c @-@ % ) , who were receiving treatment with stable doses of insulin , to one of four dapagliflozin doses ( @ , @ , @ , or @ mg ) or placebo .